id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dpc-5196	Üstün, Petek; Adışen, Esra	Factors Influencing Relapse After Omalizumab in Chronic Urticaria. Does the Method of Discontinuation Influence Relapse?	2025	8	.pdf	application/pdf	4784	291	61	Relapse time, n (%) 1-3 months 4-6 months 7-12 months >12 months 49 (49) 21 (21) 19 (19) 11 (11) Post-relapse treatment, n (%) AH Omalizumab 10 (10) 90 (90) †Patients were categorized based on their approach to discontinuing omalizumab treatment: cessation directly (300 mg every 4 weeks), pro- longing the dosing interval to 8 weeks (300 mg every 8 weeks), and reducing the dosage to 150 mg every 4 weeks. There was a statistically significant difference in post-treatment relapse rates according to the method of discontinuation (P< 0.001).	cache/dpc-5196.pdf	txt/dpc-5196.txt